Research programme: tyrosine protein kinase antibody therapeutics - ElsaLys BiotechAlternative Names: Anti-TYRO3/MERKT antibody - ElsaLys Biotech; ELB 031
Latest Information Update: 20 Dec 2016
At a glance
- Originator ElsaLys Biotech
- Developer Curie Institute; ElsaLys Biotech
- Class Antibodies
- Mechanism of Action Proto-oncogene protein c-mer modulators; TYRO3 receptor protein tyrosine kinase modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours